NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--May 12, 2006--Senesco Technologies, Inc. (“Senesco” or the “Company”) (AMEX:SNT - News) announced today that the Company’s eukaryotic translation initiation Factor 5A-1 (“Factor 5A-1" or “eIF5A-1") gene technology reduced inflammation and inhibited apoptosis in mouse experiments conducted by W. Michael Scheld, M.D., at the University of Virginia School of Medicine.
